Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AbbVie Files Maviret for Pediatric Use for Age 12 and Older
December 3, 2018
- Olympus to Launch Japan Clinical Study of Regenerative Medicine Product for Traumatic Cartilage Defects
December 3, 2018
- ADHD Treatments to Reap 50% Growth in 2026, Despite Shrinking CNS Market: Fuji Keizai
December 3, 2018
- US FDA Approves Astellas’ AML Treatment Xospata
November 30, 2018
- Celgene Files Otezla for Additional Indication of Oral Ulcers due to Behcet’s Disease
November 30, 2018
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Kowa Reps Continue Heavy GP Detailing for Parmodia in August: Anterio
November 30, 2018
- Fycompa Hits Primary Endpoint in Monotherapy PIII, Eisai Eyes Filing by March-End
November 29, 2018
- Daiichi Sankyo, Roche to Collaborate on CDx Development for DS-8201
November 29, 2018
- JCR Launches Japan’s 1st Fabrazyme Biosimilar
November 29, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
November 29, 2018
- Takeda’s Brigatinib Bags European OK for 2nd Line ALK-Positive NSCLC
November 29, 2018
- Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
- Blincyto, Eybelis Now Available in Japan
November 28, 2018
- Ono Submits Cancer Cachexia Treatment in Japan
November 28, 2018
- Pola Orbis to Transfer All Shares of Pola Pharma to Sun Pharma Global, Aiming to Focus on Beauty Care Business
November 28, 2018
- Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
November 28, 2018
- Keytruda Continues to Close in on Opdivo in July-September Global Sales
November 27, 2018
- Poteligeo Approved in Europe for Mycosis Fungoides, Sézary Syndrome: Kyowa Kirin
November 27, 2018
- HIV Drug Juluca Gets Japan Approval: ViiV
November 27, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…